Angelina Brathwaite has been a dedicated member of Brunel Canada Limited for the past 18 years, where she currently serves as Director of Life Sciences and Diversity, Inclusion, and Belonging (DIB) Leader for North America. In 2006, Angelina established Brunel’s Life Sciences vertical in Canada, building it from the ground up into a trusted business line that now supports leading pharmaceutical, biotechnology, medical device, and emerging startup organizations. Over time, her portfolio has expanded to include the food, beverage, and agriculture sectors—further strengthening Brunel’s position as a comprehensive partner across the life sciences value chain.

As a leader, Angelina is known for fostering collaboration, confidence, and growth. She empowers others to think strategically, take initiative, and deliver their best work. Her ability to recognize potential and cultivate high-performing teams has been instrumental in building long-standing client partnerships and driving sustained business success.

Beyond her corporate achievements, Angelina is deeply committed to community and industry engagement. She currently serves on the boards of Women Leaders in Pharma, Advancing Black Talent in Pharma, and the Clinical Research Association of Canada, and is a member of the Advisory Board for The Mina Project under the Learning Enrichment Foundation.

Angelina’s passion for elevating others, advancing diversity and inclusion, and building meaningful connections continues to make her a respected voice and trusted leader within both Brunel and the broader life sciences community.

Dorothy is an accomplished healthcare agency executive with over 20 years of success working with pharmaceutical clients across North America. In 2019 Dorothy founded healthcare agency “No Fixed Address (NFA) Health” in collaboration with No Fixed Address Inc., a rapidly growing independent consumer agency. Dorothy’s vision was to offer clients an insight-based and strategy-first approach to solving their business challenges, along with creative expertise that brings the consumer experience into the healthcare space. In addition to her daytime role, Dorothy is also on the Executive Leadership Team for Women Leaders in Pharma, Co-Founder of Canadian Healthcare Communication Professionals (CHCP) and a mentor with Scala Network, ABTip, and Executiv. In her free time Dorothy loves to spend time with her two teenage sons and also teaches downhill skiing.

Trilingual senior pharmaceutical executive with very strong record of generating strategic growth and putting in place innovative operational plans to grow spectacularly for new products and to protect market share for products nearing the end of their life cycle. Results-driven natural leader with strong presence who is at home negotiating at a high level or coaching and motivating his teams to meet and surpass their targets.

Roussen Pascal is the Founder and Principal Consultant of RP3 Management Consulting Inc., a boutique firm that partners with biotechnology and pharmaceutical organizations to advance programs that ultimately improve patients’ lives. With over 20 years of experience across drug development — spanning regulatory, nonclinical, clinical, and CMC disciplines — Roussen has guided teams through multiple development milestones, including IND, NDA, NDS and commercial launches across North America and internationally. Through RP3’s Guide | Orchestrate | Deliver™ framework, he helps life-sciences leaders build clarity in strategy, strengthen cross-functional alignment, and achieve successful outcomes that drive meaningful impact for patients worldwide.

Regulatory Affairs expert with 29 years experience in managing diverse and innovative portfolios and leading many highly successful teams in the Pharmaceutical Industry. Patient-focused approach with a proven track record in achieving outstanding results in multiple therapeutic areas including anti-infectives/antivirals, endocrinology, inflammation & immunology, rare diseases and vaccines. Instrumental in approval of over 20 new drugs in Canada and achieving unprecedented results with the COVID-19 vaccine.

25 years in the pharmaceutical industry focused on pricing, reimbursement and health economics.